Rapid diagnostic tests to detect pathogenic microorganisms
Diagnosis of bloodstream infections and quality control measures addressing microbial contamination safety have traditionally been based on the cultivation of pathogenic microorganisms with subsequent morphological, biochemical and immunological identification and, if applicable, antibiotic susceptibility testing. These culture-based technologies have now been adapted to microbial contamination detection of labile blood products to avoid transfusion-transmitted bloodstream infections. Major restraints of cultivation-dependent identification of pathogenic microorganisms encompass the extended time requirement until detection of growth and the limited sensitivity for slow-growing, non-cultivable or intracellular microorganisms. Therefore, rapid, non-culture-based molecular and proteomic technologies are emerging to be applied to infectious disease diagnosis, particularly in life-threatening conditions, such as bloodstream infections or meningitis.
Bloodstream infections can quickly develop to lifethreatening states, which require rapid identification of the causative microorganisms to direct initial treatment. Since 1999, the prevalence of bloodstream infections has been continuously increasing, showing a slowly growing proportion of fungaemias. Sepsis is now the third most common cause of hospital mortality with a considerable associated morbidity and economic burden. A number of molecular methods have been published over the last years for identification of selected bacteria and fungi in positive blood cultures, and a wide variety of molecular diagnostic technologies has been applied, involving standard and real-time single and multiplex PCR, restriction fragment length polymorphism and single-strand conformation polymorphism, as well as fluorescence in situ hybridisation, multiplex real-time PCR and gene microarrays. Some of these technologies identify the most relevant bacteria, including selected important resistance mechanisms causing bloodstream infections directly from positive blood cultures (e.g., Hyplex BloodScreen; BAG, Lich, Germany). Another promising development is the application of spectrometry on pathogen profiling. Starting from single colonies, a wide range of human pathogenic microorganisms can be rapidly identified within minutes by tandem mass spectrometry using an expert data analysis system (e.g., Bruker Daltonics, Bremen, Germany). However, all growth-based methods are restricted to the identification of cultivable pathogens and show limitations for slow-growing, fastidious and intracellular microorganisms. In addition, since many of the expensive and technically demanding molecular methods require at least positive growth in blood cultures or even growth of single cultures, they can only be started after positivity or even at the same time as the current growth-based biochemical identification methods and thus show limited or no significant time savings when compared to today's fully automated continuously monitoring microdilution identification systems.
A major advent for rapid diagnosis of bloodstream infections are direct identification methodologies for pathogens in blood and other primarily sterile sites, such as cerebrospinal fluid or urine. Much less information is available on these approaches without prior cultivation steps. Most of the non-culture based methods have been developed for characterisation of single pathogens from normally sterile clinical samples. However, in bacteraemia and sepsis a broad range of bacteria and fungi may be present, which differs in distinct clinical settings, with about 20 bacteria constituting 85% of the causes of bloodstream infections. The most prevalent bacteria and fungi in bloodstream infections may differ considerably with the cause of infection, e.g., slow-growing or fastidious bacteria in bacteraemia of endocarditis, respiratory pathogens in pneumonia-associated sepsis or enterobacteraceae and anaerobes following abdominal surgery. Therefore, diagnosis of bloodstream pathogens requires rapid broad-range bacterial and fungal identification technologies, such as eubacterial 16S/23S rRNA/rDNA or panfungal 8S/18S rRNA/rDNA detection with subsequent hybridisation or sequencing for identification. Very recently, multiplex real-time PCR technologies as well as microarrays have emerged to be applied to diagnose bacteraemia, allowing direct identification of pathogens from blood, some even allowing detection of important resistance mechanisms without prior cultivation within 4-6.5 h (e.g., Septifast ᮋ , Roche Diagnostics, Mannheim, Germany; VYOO ᮋ , SIRS-Lab, Jena, Germany). These approaches have been successfully applied to the identification of bloodstream pathogens despite limitations for low bacterial load in adult sepsis and lack of sensitivity for some microorganisms, but await proof of clinical advantage when compared with conventional culture. Currently, expenditures for consumables, technical equipment, as well as time and effort of trained personnel, have precluded general applicability for routine purposes.
A similar requirement of diagnostic technologies for rapid detection of potential microbial contamination also characterises quality control measures for labile blood products. Due to the limited availability of the human source for blood products, the production costs and the short storage life, particularly of the labile components, such as platelets, rapid microbial detection methods are warranted, which are sensitive for all bacterial species, reliable and preferably to be performed prior to transfusion in point-of-care testing. Today, bacterial contamination of blood components represents the most common microbiological cause of transfusion-related morbidity and mortality, since the dramatic reduction of viral transmission due to the general introduction of nucleic acid-based technology (NAT) testing. The overall prevalence of bacterially contaminated blood products is approximately 1:2500, primarily following platelet transfusion, but also occurring after transfusion of erythrocyte concentrates, haematopoietic progenitor cells or plasma. Overt transfusion-associated sepsis is a rare event estimated at 1:50,000 for platelet and 1:500,000 for erythrocyte concentrates transfused, but is marked by a high case-fatality rate. Bacterial contamination of blood products with transfusion-associated bacteraemia/sepsis accounted for 22% of the transfusion-associated case fatalities in France between 1994 and 1999 (French Haemovigilance), and for over 10% of all transfusion-related fatalities over 15 years in the USA. Therefore, several European countries introduced microbial monitoring techniques with mandatory testing for bacterial contamination in platelet concentrates as an integral part of transfusion-transmitted disease surveillance and prevention, including Scandinavia (since mid-1990), the Nether- Rapid screening methods for bacterial detection in blood products are thus being developed to allow a reliable detection of bacteria with sufficient sensitivity to essentially prevent transfusion-transmitted disease. Initially, the same automated bacterial screening methods, which had been applied in routine microbiological analysis since more than a decade, have been adapted to bacterial safety testing in blood products. Until recently, contamination screening in labile blood liquid culture methods thus was based on automated blood culture systems (e.g., BacT/ ALERT, bioMé rieux, Craponne, France; BACTEC 9240, BD Biosciences, Heidelberg, Germany; Pall eBDS, Pall Corporation, Dreieich, Germany) with a notional detection limit of 1 CFU/mL for most strains. Due to the limitations of the described culture-based screening systems, further direct rapid screening methods have been developed, which are based on fluorescent staining of bacteria with subsequent detection by flow cytometry (BD Biosciences) in a few hours, thus allowing pre-transfusion screening without reducing the availability of blood products. Alternatively, direct bacterial nucleic acid detection methods relying on panbacterial consensus sequences, e.g., 16S or 23S rRNA by real-time PCR, allow detection of 10-100 CFU/mL. Since in contrast to the diagnosis of bacteraemia/sepsis, the bacterial load in blood products may increase tremendously with storage time due to proliferation of contaminating bacteria, the sensitivity of NATs appears sufficiently reliable. The type of bacterial contamination differs with the blood products, in that platelet concentrates which are stored at 22"28C for up to 5 days Staphylococcus, Propionibacterium or Bacillus spp. prevail, while surviving pathogens in erythrocytes stored at 48C mainly constitute psychrophilic Enterobacteriaceae. Low numbers of most Gram-positive bacteria of the skin flora may not produce symptoms in normal recipients, while they may cause sepsis in the immunosuppressed, whereas some Gram-negative contaminants may also produce severe adverse reactions at low bacterial counts by virtue of their endotoxin content.
The review by Mariam Klouche and Uwe Schrö der provides a comprehensive overview on the emerging rapid technologies to detect bloodstream infections, including broad-range nucleic acid-based assays and proteomic profiling of pathogens. Besides the considerations for the interpretation of molecular and proteomic data in the diagnosis of bloodstream infections, lessons from quality control applications related to microbial safety analyses are provided. Heiner Dö ring and Alexandra Heininger provide an excellent review on the validation requirements of general and universal PCR assays for the diagnosis of human infection. The particular preanalytical considerations of sampling, the practical analytical demands and particularly the clinical utility of broad-range NAT testing for pathogenic microorganisms for infectious disease diagnosis is discussed in comparison to classic microbiological methods. The review by Thomas Montag gives a broad introduction and compact evaluation of the current culture-based and direct methods for bacterial screening of cell-based medicinal products with a focus on the particular preanalytical problems due to the manufacturing processes. The epidemiology and clinical presentation of transfusiontransmitted bacteraemia are detailed by Gabriele Walther-Wenke. Data from a large survey covering more than 8 million blood products regarding the prevalence of microbial contamination of blood products in Germany are provided. The extensive overview by Thomas Mü ller and his team covers the available methods to diagnose transmissible bacteria in blood products with a focus on automated blood culture systems. The advantages and disadvantages of the blood culture methodology are detailed and complemented by the results of a prospective study covering more than 50,000 platelet concentrates of the GERMS consortium (German Evaluation of Regular Bacterial Monitoring Study). Strategies for direct detection of bacteria in blood products by flow cytometry are presented in the thorough review by Oliver Karo and coworkers. In addition, the issue of generating bacterial standards is thoroughly addressed. Henk Reesink provides an excellent overview on the currently available methods for detection of bacterial contamination of blood products with a particular focus on 16S rDNA-based NAT methods. Besides detailed information regarding the panbacterial PCR-based approach, he scrutinises the potential pitfalls and preanalytical considerations, including processing of microbial DNA contamination. The review by Thomas Montag and his team, Paul-Ehrlich Institut -the National Medicinal Products Licensing Office of the German Ministry of Health -provides a prospect of the envisaged microbiological safety strategy for cellular blood products from the perspective of regulatory affairs. The conceivable introduction of a new class of microbiological diagnostic tests and the criteria for mandatory testing of blood products as exemplified for Germany is discussed.
In this series of reviews, the currently available and upcoming rapid diagnostic screening methods for detection and identification of bacteria and fungi for diagnosis of bloodstream infections in humans, as well as for quality control measures to ascertain microbial safety of blood products to avoid transfusion-transmitted bacteraemia, are reviewed. The advantages and caveats are outlined and practical information, including technical requirements, complexity, qualification of personnel and investments, is gathered to help to select the optimal technology. Particular focus is set on the clinical interpretation of the results to help to integrate novel technologies into diagnosis with the appropriate considerations. 
